The role of primary care in opioid prescribing for head and neck cancer (HNC) survivors.

Authors

null

Talya Salz

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

Talya Salz, Akriti Mishra Meza, Sankeerth Jinna, Allison Lipitz-Snyderman, Natalie Moryl, Anuja Kriplani, Kathryn Ries Tringale, James Flory, Patrick T Bradshaw, Deborah Korenstein

Organizations

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, New York, NY, University of California, Berkeley, Berkeley, CA

Research Funding

Other Foundation
Seaver Foundation Cancer and Aging Grant

Background: Older HNC survivors often experience post-treatment pain, and they have concerningly high rates of unsafe opioid prescribing (e.g., high doses, concurrent benzodiazepines). Interventions to improve opioid safety should target providers who prescribe opioids to HNC survivors. We hypothesized that oncologists were responsible for most opioid prescribing to HNC survivors, but that involvement of primary care providers (PCPs) as prescribers increased over time after treatment. Methods: Using linked Surveillance, Epidemiology, and End Results (SEER) registry and Medicare claims data, we identified adults age >65 diagnosed 2014-2017 with stage I-III HNC with ≥6 months treatment-free follow-up prior to censoring at further treatment, new cancer, hospice, death, or end 2019. Starting 1 month after treatment completion, all opioid fills were assigned to a prescriber specialty: oncology (medical, radiation, surgical), surgery, primary care (internal medicine, family practice, geriatrics), pain, or other. Prescriber patterns were summarized at the fill and patient levels for each year of follow-up. Results: Among 5494 HNC survivors with median 2.1 years of treatment-free follow-up, 3092 (56%) had ≥1 opioid fill. At the fill level, almost half of all opioids (47%) were dispensed in the first year after treatment completion, with fewer fills each subsequent year. Contrary to our hypothesis, only 9% of all fills were prescribed by oncologists. Half of all fills were prescribed by PCPs; 14% were prescribed by pain specialists and 9% by surgeons. At the patient level, on average, each survivor had 34% of their opioid fills prescribed by primary care providers, followed by 24% by surgeons and 10% by oncologists. The proportion of survivors’ fills prescribed by PCPs remained high (36%-42% of each survivor’s fills) across all years, while proportion of each survivor’s fills prescribed by oncologists declined from 14% to 2% over years of follow-up. (See Table). Conclusions: PCPs prescribe a greater proportion of HNC survivors’ opioids than oncologists and surgeons combined. While oncologists’ and surgeons’ role as opioid prescribers declines over time, primary care involvement in opioid prescribing remains high throughout survivorship, suggesting that PCPs manage cancer-related pain, non-cancer pain is prevalent after HNC, or both. Interventions to address unsafe opioid use among HNC survivors should target the primary care setting, as is typical for opioid-reduction efforts in the non-cancer population.

Years After Treatment Completion123456
# Survivors alive each year5494434430061689843287
# Survivors receiving opioids (%)2195 (40%)1352 (32%)775 (26%)389
(23%)
174
(21%)
44 (15%)
% of each survivor’s opioid fills prescribed by each specialty
Primary care374043434042
Oncology1453332
Surgery202120211915
Pain678985
Other202323222736
Missing554222

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship

Sub Track

Care Coordination, Cost, and Education

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 480)

DOI

10.1200/OP.2023.19.11_suppl.480

Abstract #

480

Poster Bd #

L6

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Prescribers of opioids for head and neck cancer (HNC) survivors.

First Author: Talya Salz

Abstract

2024 ASCO Quality Care Symposium

Opioid tapering and discontinuation for head and neck cancer (HNC) survivors.

First Author: Talya Salz

First Author: Nosayaba Osazuwa-Peters